News Story: Full Text
Sponsored By
Genentech Biooncology
Please Click On The Above Banner For More Details
Braintumor Website

 

Allos Therapeutics Appoints Regulatory Affairs and Clinical Development Executives (PR Newswire) ...The Company is conducting a pivotal Phase III trial for the treatment of metastatic brain tumors with its lead clinical candidate, RSR13.......By increasing tumor oxygenation, RSR13 has the potential to enhance the efficacy of standard radiation therapy... - Aug 22 11:30 AM ET



Website: http://biz.yahoo.com/prnews/010822/law046_2.html

Posted on: 08/22/2001

"Yahoo - Allos Therapeutics Appoints Regulatory Affairs and Clinical Development Executives"
Yahoo! Finance Finance Home - Yahoo! - Help
PR Newswire

[ Latest Headlines | Market Overview | News Alerts ]


Related Quotes
ALTH
4.67
-0.07
delayed 20 mins - disclaimer

Wednesday August 22, 11:30 am Eastern Time

Press Release

SOURCE: Allos Therapeutics, Inc.

Allos Therapeutics Appoints Regulatory Affairs and Clinical Development Executives

DENVER, Aug. 22 /PRNewswire/ -- Allos Therapeutics, Inc. (Nasdaq: ALTH - news) today announced two new appointments. Markus F. Herzig was named Vice President of Regulatory Affairs and will oversee Allos' national and international regulatory activities. He will report to Michael J. Gerber, M.D., Senior Vice President, Clinical Development and Regulatory Affairs. Pablo J. Cagnoni, M.D., was appointed Director, Clinical Development. In this position, Dr. Cagnoni will be vital in the development of clinical trials to evaluate Allos' pipeline of products. He will report to Jean-Francois Liard, M.D., Vice President of Clinical Development.

Mr. Herzig, 56, joins Allos from OraPharma, Inc., where he was Executive Director, Regulatory Affairs and Quality Assurance. He has also held key management positions at Sandoz Pharmaceuticals Corp., Organon Inc., Novo Nordisk Pharmaceuticals Inc. and Takeda Pharmaceuticals America, Inc. Mr. Herzig has been responsible for nearly 30 INDs and 6 NDAs in several different therapeutic areas.

"Markus brings nearly two decades of regulatory affairs and project management experience to Allos," said Dr. Gerber. "His experience will be invaluable as we move closer to completing our Phase III study of RSR13 and preparing for an NDA submission to the FDA. We are very pleased to have someone of his caliber on the Allos team."

Dr. Cagnoni, 38, was most recently Assistant Professor of Medicine and a member of the Bone Marrow Transplant Program at the University of Colorado. Prior to moving to Colorado, Dr. Cagnoni trained in hematology/oncology at The Mount Sinai Medical Center in New York. Dr. Cagnoni has presented at over 30 meetings, authored or co-authored more than 40 articles, 16 book chapters and over 40 abstracts.

"We look forward to benefiting from Pablo's expertise in our efforts to complete the clinical development of RSR13 and to prepare for its commercialization," said Dr. Liard. "Pablo will also contribute greatly to the acquisition and development of new compounds."

About Allos Therapeutics

Allos Therapeutics, Inc. is a pharmaceutical company focused on developing and commercializing innovative small molecule drugs, initially for improving cancer treatments. The Company is conducting a pivotal Phase III trial for the treatment of metastatic brain tumors with its lead clinical candidate, RSR13. RSR13 is a synthetic small molecule that increases the release of oxygen from hemoglobin, the oxygen carrying protein contained within red blood cells. The presence of oxygen in tumors is an essential element for the effectiveness of radiation therapy and some chemotherapy agents in the treatment of cancer. By increasing tumor oxygenation, RSR13 has the potential to enhance the efficacy of standard radiation therapy and certain chemotherapeutic drugs. Unlike chemotherapeutics or other radiosensitizers, RSR13 does not have to cross the blood brain barrier and enter the tumor for efficacy. Enhancement of oxygen release from hemoglobin to oxygenate the tumor is the means of enhancing the effectiveness of radiation therapy and chemotherapy. For more information about the Company, please consult www.allos.com

SOURCE: Allos Therapeutics, Inc.

Email this story - Most-emailed articles - Most-viewed articles


More Quotes and News:Allos Therapeutics Inc (NasdaqNM:ALTH - news)
Related News Categories: biotech, medical/pharmaceutical

Help


Copyright © 2001 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
Copyright © 2001 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Questions or Comments?
"
Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740